1 INTRODUCTION
1.1 DEFINITION
1.2 SCOPE OF STUDY
1.2.1 RESEARCH OBJECTIVE
1.2.2 ASSUMPTIONS & LIMITATIONS
1.2.2.1 ASSUMPTIONS
1.2.2.2 LIMITATIONS
1.3 MARKET STRUCTURE:
2 RESEARCH METHODOLOGY
2.1 RESEARCH PROCESS:
2.2 PRIMARY RESEARCH
2.3 SECONDARY RESEARCH:
3 MARKET DYNAMICS
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 MACROECONOMIC INDICATORS
4 MARKET FACTOR ANALYSIS
4.1 PORTERS FIVE FORCES MODEL
4.2 BARGAINING POWER OF SUPPLIERS
4.3 BARGAINING POWER OF BUYERS
4.4 THREAT OF NEW ENTRANTS
4.5 THREAT OF SUBSTITUTES
4.6 INTENSITY OF RIVALRY
5. GLOBAL APHERESIS MARKET, BY PRODUCT
5.1 DEVICES
5.1.1 PLASMA SEPARATORS
5.1.2 PLATELETS SEPARATORS
5.1.3 OTHER
5.2 DISPOSABLES
6. GLOBAL APHERESIS MARKET, BY PROCEDURES
6.1 PLATELETPHERESIS
6.2 LEUKAPHERESIS
6.3 ERYTHROCYTAPHERESIS
6.4 PLASMAPHERESIS
6.5 OTHER
7. GLOBAL APHERESIS MARKET, BY METHODS
7.1 CENTRIFUGATION
7.1.1 CONTINUOUS FLOW CENTRIFUGATION
7.1.2 INTERMITTENT FLOW CENTRIFUGATION
7.1.3 OTHER
7.2 FILTRATION
8. GLOBAL APHERESIS MARKET, BY APPLICATION
8.1 ONCOLOGICAL DISEASES
8.2 RENAL DISEASES
8.3 CARDIOVASCULAR DISEASES
8.4 HAEMATOLOGICAL DISEASES
8.5 IMMUNOLOGICAL DISEASES
8.6 NEUROLOGICAL DISEASES
8.7 OTHER
9. GLOBAL APHERESIS MARKET, BY END USERS
9.1 BLOOD BANKS
9.2 HOSPITALS
9.3 OTHER
10. GLOBAL APHERESIS MARKET, BY REGION
10.1 INTRODUCTION
10.2 AMERICA
10.2.1 NORTH AMERICA
10.2.1.1 US
10.2.1.2 CANADA
10.2.2 SOUTH AMERICA
10.3 EUROPE
10.3.1 WESTERN EUROPE
10.3.1.1 GERMANY
10.3.1.2 FRANCE
10.3.1.3 ITALY
10.3.1.3 SPAIN
10.3.1.5 UK
10.3.1.6 REST OF WESTERN EUROPE
10.3.2 EASTERN EUROPE
10.4 ASIA-PACIFIC
10.4.1 JAPAN
10.4.2 CHINA
10.4.3 INDIA
10.4.4 AUSTRALIA
10.4.5 REPUBLIC OF KOREA
10.4.6 REST OF ASIA-PACIFIC
10.5 MIDDLE EAST & AFRICA
10.5.1 UNITED ARAB EMIRATES
10.5.2 SAUDI ARABIA
10.5.3 OMAN
10.5.4 KUWAIT
10.5.5 QATAR
10.5.6 REST OF MIDDLE EAST & AFRICA
11. COMPETITIVE LANDSCAPE
11.1 MAJOR STRATEGIES ADOPTED BY MARKET PLAYERS
11.1.1 STRATEGIC PARTNERSHIP
11.1.2 MERGER & ACQUISITION
12 COMPANY PROFILE
12.1 HAEMONETICS CORPORATION
12.1.1 OVERVIEW
12.1.2 PRODUCT OVERVIEW
12.1.3 FINANCIALS
12.1.4 KEY DEVELOPMENTS
12.2 FRESENIUS MEDICAL CARE
12.2.1 OVERVIEW
12.2.2 PRODUCT OVERVIEW
12.2.3 FINANCIALS
12.2.4 KEY DEVELOPMENTS
12.3 TERUMO BCT, INC
12.3.1 OVERVIEW
12.3.2 PRODUCT OVERVIEW
12.3.3 FINANCIALS
12.3.4 STRATEGY
12.3.5 KEY DEVELOPMENT
12.4 ASAHI KASEI MEDICAL CO. LTD
12.4.1 OVERVIEW
12.4.2 PRODUCT OVERVIEW
12.4.3 FINANCIALS
12.4.4 KEY DEVELOPMENTS
12.5 HEMACARE CORPORATION
12.5.1 OVERVIEW
12.5.2 PRODUCT OVERVIEW
12.5.3 FINANCIALS
12.5.4 KEY DEVELOPMENTS
12.6 B. BRAUN MELSUNGEN AG
12.6.1 OVERVIEW
12.6.2 PRODUCT OVERVIEW
12.6.3 FINANCIALS
12.6.4 KEY DEVELOPMENTS
12.7 CERUS CORPORATION
12.7.1 OVERVIEW
12.7.2 PRODUCT OVERVIEW
12.7.3 FINANCIALS
12.7.4 KEY DEVELOPMENTS
12.8 OTHER
13 CONCLUSION
14.1 KEY FINDINGS
14.1.1 FROM CEO’S VIEWPOINT
14.1.2 UNMET NEEDS OF THE MARKET
14.2 KEY COMPANIES TO WATCH
14.3 PREDICTION OF APHERESIS INDUSTRY
15 APPENDIX
